In downstream vaccine manufacturing, Peste des petits ruminants virus, live strain Clone 9, is handled as a clarified virus harvest rather than a conventional chemical API. The strain is generally produced in Vero cell culture or primary caprine kidney cell culture in roller bottles, cell factories, or single-use bioreactors. Harvested viral fluid is clarified by depth filtration and membrane filtration, then blended with a stabilizer base containing sucrose, lactalbumin hydrolysate, and dextran-40 in phosphate buffer. The formulated bulk is filled into Type I glass vials at 2°C–8°C using peristaltic or rotary piston filling pumps. Filled vials are transferred to production-scale lyophilizers with shelf areas from 20 m² to 50 m². Primary drying is commonly run at shelf temperatures from −40°C to −10°C and chamber pressure from 80 µbar to 200 µbar. Residual moisture is controlled by Karl Fischer titration according to USP 921; typical release limits are set at or below 2.5% w/w because higher moisture accelerates loss of infectivity under tropical ambient storage. The minimum release titer for monovalent injection is commonly specified at 10^2.5 TCID50 per 1.0 mL reconstituted caprine dose. Production-scale failure modes observed in lyophilization include cake collapse in vials with fill depth above 12 mm, stopper seating defects caused by partial vacuum loss, and uneven residual moisture between edge and center shelf positions. These limitations require that fill volume, stopper type, and lyophilization ramp rate be tightly matched to the freeze-dried cake design.

When Combined PPR–Sheep Pox Lyophilized Formulations Are Co-Filled

In combined live vaccine manufacturing, Clone 9 PPR antigen is blended with attenuated sheeppox or goatpox antigen before lyophilization. The two viruses show different thermostability profiles, so the lyophilization cycle is deliberately anchored to the more heat-labile Clone 9 PPR component. A representative stabilizer system used in published combined-vaccine dossiers contains 5% w/v sucrose, 1% w/v gelatin, and 0.5% w/v lactalbumin hydrolysate; final ratios are established through fractional factorial stability studies because freeze-dried cake porosity and reconstitution time change with each stabilizer. The diluent is typically sterile water for injection or phosphate-buffered saline in 1.0 mL or 2.0 mL volumes. Combined vaccine incompatibility risk increases when the diluent contains traces of chlorine or when rubber stoppers contain high volatile silicone residues; laboratory studies show that these contaminants can reduce post-reconstitution titer by more than 0.5 log10 TCID50 within 4 h. Filling lines for combined live vaccines must separate monovalent and combined campaigns because cleaning-in-place with alkaline detergents is not sufficient to eliminate cross-contaminating live virus; dedicated product-contact parts and sterile tubing sets are used. A line running at 12,000 vials/hour typically requires a holding time at 4°C not exceeding 8 h between bulk formulation and lyophilization to keep infectious titer loss below 0.3 log10 TCID50.

What Limits Tablet and Capsule Compaction for a Live Paramyxovirus Antigen?

Tablet and capsule presentations are not used for live Clone 9 PPR vaccine because direct compression and dry granulation destroy the envelope integrity of this paramyxovirus and reduce infective titer to unacceptable levels. A live viral antigen embedded in a tablet matrix faces three simultaneous constraints: compression pressure, frictional heating, and the low-moisture environment required for sugar-stabilized solids. Rotary tablet presses operating at compression pressures from 50 MPa to 200 MPa generate localized die-wall temperatures that can exceed the critical inactivation threshold of PPR virus. Thermal stability data for liquid PPR preparations show rapid first-order infectivity loss at 37°C, and even lyophilized matrix loses measurable titer after prolonged storage above 25°C. Capsule filling with low-moisture granules requires final granule moisture below 1.0% w/w, but freeze-dried PPR antigen containing sucrose or trehalose is hygroscopic and rehydrates during capsule filling unless relative humidity is maintained below 15% RH. Gelatin and hypromellose capsule shells also introduce residual aldehyde impurities that can crosslink viral surface glycoproteins. Published data for a directly compressible live PPR vaccine tablet is limited; current industrial practice confines Clone 9 antigen to lyophilized parenteral presentations, and any oral solid-dose development would require an entirely separate inactivation strategy that falls outside the live vaccine specification.

For strategic stockpile and emergency reconstitution applications, Clone 9 bulk is lyophilized in multidose vials and then held in national or regional antigen banks. The freeze-dried powder is not a dry oral premix and is not mixed into feed or drinking water; it is reconstituted with sterile diluent immediately before subcutaneous injection in small ruminants. Multidose vials containing 50 doses or 100 doses are processed in ISO 14644-1 Grade A aseptic filling lines with automatic stopper insertion at chamber pressure below 1×10^-4 mbar. The main production bottleneck is not lyophilization capacity but cake homogeneity in large-volume vials; 10 mL fill volumes frequently show micro-collapse at the bottom-center when fill depth exceeds 12 mm. Manufacturers therefore reduce fill depth or include an annealing step at −20°C for 2 h during freezing to improve ice crystal uniformity. Reconstitution in field conditions is performed with cold sterile diluent at 2°C–8°C; post-reconstitution potency is generally retained for no more than 6 h because live PPRV is sensitive to ambient heat and ultraviolet light. Aqueous solution intermediates are held at 2°C–8°C for not more than 8 h before lyophilization; pH is maintained between 7.2 and 7.6 with phosphate buffer, and osmolality is adjusted to 280 mOsm/kg–320 mOsm/kg. The solution is passed through a 0.22 µm membrane filter before vial filling; filter fouling is a known production issue when cell debris or aggregates exceed 0.1% w/v. Ready-to-use solution presentations are not technically feasible for this live vaccine because extrapolated potency loss at 4°C over 7 days exceeds the maximum allowable release limit in most national specifications.

Bulk Freeze-Dried Granule Feedstock for Regional Formulators

Regional formulators receive Clone 9 lyophilized granules as a bulk antigen intermediate for diluent-specific filling. Granules are prepared by lyophilizing formulated bulk in stainless steel trays, sieved through 2.0 mm mesh, and packed in laminated aluminum foil with desiccant. Storage at −20°C or below is used for multi-year stockpiles; residual moisture is controlled below 1.5% by USP 921. Oversize granules above 2.0 mm delay reconstitution beyond 3 min; fine particles below 0.15 mm create dust loss during aseptic transfer. This presentation is not for direct oral use.

Freeze-Drying Parameters That Govern Clone 9 Infectivity Retention in Multidose Injection Vials

For multidose injection presentations, the lyophilized viral cake must meet both potency and sterility release criteria. Primary drying shelf temperature is set between −45°C and −25°C; if the product temperature reaches the collapse temperature, the dried matrix forms a glassy scum with reduced porosity and prolonged reconstitution time. Chamber pressure is controlled between 50 µbar and 200 µbar; lower pressure accelerates sublimation but also increases the risk of vial edge overheating and non-uniform heat transfer. Secondary drying is conducted at shelf temperatures from 20°C to 35°C for 4 h to 12 h; the endpoint is set by chamber moisture rise and product temperature rather than a fixed time alone. Stoppers are closed under vacuum or dry nitrogen; oxygen in headspace accelerates oxidative damage to viral envelope proteins, so a headspace oxygen level below 1.0% is targeted using nitrogen backfill after lyophilization. The final reconstituted volume into multidose vials is usually 10 mL to 100 mL, and the diluent may contain phosphate-buffered saline with 0.9% w/v sodium chloride. Antimicrobial preservatives such as phenol or benzyl alcohol are generally incompatible with live PPRV and are omitted from the diluent. The total solids content of the pre-lyophilization solution is maintained between 5% and 10% w/v to avoid cake collapse at low solids and cracking at high solids.

Diagnostic reference use of the same lyophilized powder is confined to serum neutralization proficiency panels in WOAH and national reference laboratories.